Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group

Executive Summary

• Ventripoint Diagnostics Ltd. announced a strategic collaboration with the Health Division of the Montecristo Group to explore expanded cardiac screening, clinical research, and the implementation of its VMS+™ AI-assisted echocardiography platform in Costa Rica.
• The partnership aims to improve access to advanced cardiac diagnostics for both public and private healthcare systems in Costa Rica, with a specific focus on remote screening for congenital and structural heart disease.
• The collaboration will involve technology deployment, research partnerships, and Clinical Research Organization (CRO) programs to support new care models and enhance diagnostic accuracy in underserved or remote communities.

Key Details

• Parties Involved: Ventripoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) and the Health Division of the Montecristo Group (specifically the Metropolitano Research Institute).
• Core Technology: Ventripoint’s VMS+™ cardiac imaging platform, which utilizes proprietary Knowledge Based Reconstruction technology for accurate volumetric cardiac measurements.
• Strategic Objectives:
  • Expand access to advanced cardiac diagnostics in Costa Rica.
  • Implement remote screening for congenital and structural heart disease.
  • Integrate VMS+™ technology into clinical research and clinical trial programs.
  • Deploy AI-assisted echocardiography solutions for patients across public and private healthcare sectors.
• Operational Focus: Enhancing the accuracy of cardiac imaging and enabling earlier detection of heart conditions, particularly in underserved or remote communities.
• Research Component: The Metropolitano Research Institute will serve as the research partner, leveraging expertise in clinical research execution and large-scale screening deployment.
• Market Context: The VMS+ system is designed as an affordable, gold-standard alternative to MRI, supported by regulatory market approvals in the U.S., Europe, and Canada, and compatible with all ultrasound systems from any vendor.

Notable Quotes

• Hugh MacNaught, President & CEO of Ventripoint Diagnostics: “We are excited to collaborate with the Health Division of the Montecristo Group to enable the adoption of VMS+™ technology in Costa Rica. Their strong healthcare network, commitment to affordable high-quality care, and passion for innovation make them an ideal partner as we work to expand access to advanced cardiac diagnostics and support clinical research opportunities in central America.”
• Catalina Ulloa, Director, Metropolitano Research Institute, Hospital Metropolitano, Grupo Montecristo: “At the Metropolitano Research Institute, we are proud to serve as the research partner of Ventripoint Diagnostics in Costa Rica, leveraging our expertise in clinical research execution and large-scale screening deployment in Costa Rica. This partnership enables us to translate advanced AI-driven cardiac imaging into real-world impact by expanding early detection, improving diagnostic accuracy, and increasing access to high-quality cardiovascular care.”